Bihlet, A. R., Balchen, T., Goteti, K., Sonne, J., Ladel, C., Karsdal, M. A., . . . Guehring, H. (2024). Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis. ACR Open Rheumatology, 6(4), 205-214.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Bihlet, Asger Reinstrup, et al. "Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis."
ACR Open Rheumatology 6, no. 4 (2024): 205-214.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Bihlet, Asger Reinstrup, et al. "Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis."
ACR Open Rheumatology, vol. 6, no. 4, 2024, pp. 205-214.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.